Literature DB >> 25575137

Adenosine kinase expression in cortical dysplasia with balloon cells: analysis of developmental lineage of cell types.

Guoming Luan1, Qing Gao, Feng Zhai, Jian Zhou, Changqing Liu, Yin Chen, Tianfu Li.   

Abstract

Focal cortical dysplasia type IIB (FCDIIB) is a developmental malformation of the cerebral cortex that is associated with pharmacoresistant epilepsy. Overexpression of adenosine kinase (ADK) has been regarded as a pathologic hallmark of epilepsy. We hypothesized that the epileptogenic mechanisms underlying FCDIIB are related to abnormal ADK expression. We used immunohistochemistry to examine the expression of ADK and of heterogeneous cell population markers of astrocytes (glial fibrillary acidic protein), immature glia (vimentin), immature neurons (neuronal class III beta-tubulin, TUJ1), multipotential progenitor cells (nestin), mature neurons (microtubule-associated protein 2), and antiapoptotic gene products (Bcl-2) in surgically resected human epileptic cortical specimens from FCDIIB patients (n = 20). Expression patterns were compared with those in normal autopsy (n = 6) and surgical control (n = 6) brain samples. Balloon cells in FCDII lesions were immunoreactive for ADK (77%) and balloon cells expressing the different cell markers expressing different degrees of ADK. Adenosine kinase expression assessed by Western blot and enzymatic activity were also greater in FCD versus control samples. These results suggest that upregulation of ADK is a common pathologic component of FCDIIB. Adenosine kinase might, therefore, be a target in the treatment of epilepsy associated with FCD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25575137     DOI: 10.1097/NEN.0000000000000156

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

1.  Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy.

Authors:  Cristiana Pelorosso; Françoise Watrin; Valerio Conti; Emmanuelle Buhler; Antoinette Gelot; Xiaoxu Yang; Davide Mei; Jennifer McEvoy-Venneri; Jean-Bernard Manent; Valentina Cetica; Laurel L Ball; Anna Maria Buccoliero; Antonin Vinck; Carmen Barba; Joseph G Gleeson; Renzo Guerrini; Alfonso Represa
Journal:  Hum Mol Genet       Date:  2019-11-15       Impact factor: 6.150

Review 2.  The Interaction Between Sleep and Epilepsy.

Authors:  Annie H Roliz; Sanjeev Kothare
Journal:  Curr Neurol Neurosci Rep       Date:  2022-07-08       Impact factor: 6.030

Review 3.  Metabolic Aspects of Adenosine Functions in the Brain.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Maria Grazia Tozzi
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

Review 4.  Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities.

Authors:  Fan Chen; Xinghui He; Guoming Luan; Tianfu Li
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

5.  Abnormalities of signal transduction networks in chronic schizophrenia.

Authors:  Jennifer L McGuire; Erica A Depasquale; Adam J Funk; Sinead M O'Donnovan; Kathryn Hasselfeld; Shruti Marwaha; John H Hammond; Vahram Hartounian; James H Meador-Woodruff; Jarek Meller; Robert E McCullumsmith
Journal:  NPJ Schizophr       Date:  2017-09-12

6.  Genome Editing in Neuroepithelial Stem Cells to Generate Human Neurons with High Adenosine-Releasing Capacity.

Authors:  Daniel Poppe; Jonas Doerr; Marion Schneider; Ruven Wilkens; Julius A Steinbeck; Julia Ladewig; Allison Tam; David E Paschon; Philip D Gregory; Andreas Reik; Christa E Müller; Philipp Koch; Oliver Brüstle
Journal:  Stem Cells Transl Med       Date:  2018-03-28       Impact factor: 6.940

Review 7.  Emerging Role of Purine Metabolizing Enzymes in Brain Function and Tumors.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Edoardo Petrotto; Maria Grazia Tozzi
Journal:  Int J Mol Sci       Date:  2018-11-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.